DHSC: alert issued for use of antiviral medicines in cases of influenza
- Benralizumab recommended for severe asthma in final draft guidance.
- Recall issued for some batches of irbesartan/hydrochlorothiazide film-coated tablets.
- EAMS positive scientific opinion for atezolizumab as a treatment of metastatic non-squamous non-small cell lung cancer with EGFR/ALK mutations.
- Alert issued for use of antiviral medicines in cases of influenza.
- Approval of home use for the second stage of early medical abortion.
- New maternity plans announced to improve safety and continuity of care.
- GP IT Futures framework set to replace outdated IT systems.
- Health Harms campaign launched to encourage smokers to quit.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
BENRALIZUMAB RECOMMENDED FOR SEVERE ASTHMA IN FINAL DRAFT GUIDANCE
NICE has published a final appraisal document which recommends benralizumab (Fasenra), as an add-on therapy, as an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, only if:
- the person has agreed to and followed the optimised standard treatment plan and
- they have an eosinophil count of 300 cells per microlitre or more, either are taking maintenance oral corticosteroids or have had four or more exacerbations in the past 12 months, or both (that is, are eligible for mepolizumab), or
- they have an eosinophil count of 400 cells per microlitre or more with three or more exacerbations in the past 12 months (that is, are eligible for reslizumab).
- the company provides it according to the commercial arrangement.
It is the third biological treatment for severe eosinophilic asthma approved for NHS use by NICE, following mepolizumab in December 2016 and reslizumab in October 2017. NICE’s earlier appraisal consultation document (ACD) had said benralizumab was not cost-effective. An improved patient access scheme from AstraZeneca made it cost-effective for people eligible for reslizumab (but not those eligible for mepolizumab) at a second ACD, and then was revised again to make it cost-effective for both in the FAD. Benralizumab is given as an injection every four weeks for the first three doses, and every eight weeks thereafter. This makes it potentially more convenient than mepolizumab, which is also injected, and reslizumab, an intravenous infusion, both of which are given every four weeks throughout treatment.
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
RECALL ISSUED FOR SOME BATCHES OF IRBESARTAN/HYDROCHLOROTHIAZIDE FILM-COATED TABLETS
Actavis Group PTC EHF is recalling some batches of Irbesartan/Hydrochlorothiazide 300/12.5mg Film-coated Tablets and Irbesartan/Hydrochlorothiazide 150/12.5mg Film-coated Tablets due to possible contamination with N‑nitrosodiethylamine (NDEA). Healthcare professionals are advised to:
- Stop supplying the listed batches immediately. Quarantine all remaining stock and return it to the supplier using the supplier’s approved process.
- Advise patients not to stop taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.
- Discuss alternative treatments with patients in the unlikely event of supply issues for Irbesartan containing products.
EAMS POSITIVE SCIENTIFIC OPINION FOR ATEZOLIZUMAB
Roche Products Limited was given a positive scientific opinion under the early access to medicines scheme (EAMS) for atezolizumab in combination with bevacizumab, paclitaxel and carboplatin as a treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR activating or ALK positive tumour mutations after failure of appropriate targeted therapies.
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
- EAMs scientific opinion – background information for Medical Directors
Information and details regarding patient access in England, Northern Ireland, Scotland and Wales is also provided.
DEPARTMENT OF HEALTH AND SOCIAL CARE
ALERT ISSUED FOR USE OF ANTIVIRAL MEDICINES IN CASES OF INFLUENZA
The Department of Health and Social Care has issued an alert regarding the use of antiviral medicines in cases of influenza. Surveillance data indicates an increase in influenza cases in the community. Prescribers may now prescribe and pharmacists may now supply antiviral medicines for the prophylaxis and treatment of influenza at NHS expense. This is in accordance with NICE guidance, and Schedule 2 to the National Health Service (General Medical Services Contracts (Prescription of drugs etc) Regulations 2004). Information on clinical at-risk groups and patients eligible for treatment in primary care at NHS expense with either oseltamivir or zanamivir is available from Public Health England. Hospital clinicians are advised to continue prescribing antiviral medicines for patients whose illness is confirmed or clinically suspected to be due to influenza, in accordance with Public Health England guidance for the treatment of complicated influenza.
APPROVAL OF HOME USE FOR THE SECOND STAGE OF EARLY MEDICAL ABORTION
The Secretary of State for Health and Social Care has approved the home of a pregnant woman in England who is undergoing treatment for termination of pregnancy as a class of place where the second stage of treatment for early medical abortion may be carried out. The treatment must be carried out in the following manner: (a) the pregnant woman has attended a clinic where she has been prescribed Mifepristone and Misoprostol to be taken for the purposes of termination of her pregnancy; and (b) the pregnant woman has taken the Mifepristone at the clinic, wants to carry out the second stage of treatment at home and the gestation of the pregnancy has not exceeded nine weeks and six days at the time the Mifepristone is taken.
NEW MATERNITY PLANS ANNOUNCED TO IMPROVE SAFETY AND CONTINUITY OF CARE
The Department of Health and Social Care has announced new maternity plans that aim to improve the safety, quality and continuity of care in order to halve stillbirths, maternal and infant deaths as well as serious brain injuries in new-born babies by 2025. The plans include:
- a redesign of neonatal services, by expanding staff numbers especially neonatal nurses, specialists and new roles for allied health professionals
- digitising the paper child health record known to parents as the ‘red book’
- piloting the digitisation of maternity records for 100,000 women by the end of 2019 to help women make choices about their care in a more convenient way
- improved accommodation for critically ill new-born babies and support from dedicated care co-ordinators from 2021 to 2022
- wider availability of physiotherapy for the one in three women who experience incontinence after childbirth
- asking all maternity services to deliver an accredited, evidence-based infant feeding programme in 2019 to 2020, such as the UNICEF Baby Friendly initiative.
GP IT FUTURES FRAMEWORK SET TO REPLACE OUTDATED IT SYSTEMS
The Secretary of State for Health and Social Care has announced that outdated IT systems in GP practices will be replaced with the GP IT Futures framework to improve and encourage technology companies access to the NHS market. The framework will look at how patient data will be moved to modern cloud services to allow clinicians and patients to securely access information in real time. It is expected that the changes will save staff time and reduce delays by allowing digitised flows of information between GP practices, hospitals and social care settings. In addition, the new standards, developed by NHS Digital, will introduce minimum technical requirements so systems can talk to each other securely and are continuously upgradable. Any system that does not meet these standards will not be used by the NHS and the government will look to end contracts with providers that do not understand these principles for the health and care sector.
PUBLIC HEALTH ENGLAND
HEALTH HARMS CAMPAIGN LAUNCHED TO ENCOURAGE SMOKERS TO QUIT
Public Health England has a new film demonstrating the personal harm to health from smoking as part of their Health Harms campaign, which encourages smokers to attempt to quit this January. Public Health England also offers a personal quit plan, which is a free and easy-to-use digital tool to help smokers find the right support to help them quit, taking into account how much they smoke, and any quitting support used previously. To find out more about the range of free support and tools available to help people quit smoking, visit the Smokefree website.